Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities

Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG

MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Indian doctor participates in Jordan’s first robotic radical hysterectomies

Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split

The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector

Bayer starts Phase III trial in non-small cell lung cancer

First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations

Royal Sense launches multiple products in pharmaceutical category

Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale

Pfizer launches digital platform ‘PfizerForAll’

PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care

Merck receives EC approval for Winrevair for treatment of PAH

Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe